Publications by authors named "J De Champlain"

Article Synopsis
  • Infectious intestinal protozoan pathogens significantly contribute to health issues globally, particularly affecting children in low- and middle-income countries due to their underdeveloped immune systems and undernutrition.
  • * The severity of symptoms in infected children can range from no symptoms to life-threatening conditions, influenced by various factors like nutritional status, immune response, and gut microbiome composition.
  • * Damage to intestinal cells by these parasites can hinder nutrient absorption, leading to long-term consequences such as stunted growth and reduced cognitive development; existing treatments may also adversely affect gut health.
View Article and Find Full Text PDF

Over 25% of adults ≥65 years of age have type 2 diabetes (T2D). Individualization of care is important in older adults with T2D, with treatment targets and therapeutic approaches informed by patient-specific medical, psychosocial, functional, and social considerations. Fixed-ratio combination injectable products offer unique benefits in older adults, including reduction of both fasting and postprandial glucose, low hypoglycemia risk, lack of weight gain, fewer gastrointestinal side effects, strong durability of effect, and the potential for medication regimen simplification.

View Article and Find Full Text PDF

Rationale: Ceruloplasmin antioxidant function is mainly related to its ferroxidase I (FeOxI) activity, which influences iron-dependent oxidative and nitrosative radical species generation. Peroxynitrite, whose production is increased in heart failure (HF), can affect ceruloplasmin antioxidant function through amino acid modification.

Objective: We investigated the relationship between FeOxI and ceruloplasmin tyrosine and cysteine modification and explored in a cohort of patients with HF the potential clinical relevance of serum FeOxI.

View Article and Find Full Text PDF

Background: An accurate prognosis prediction represents a key element in chronic heart failure (CHF) management. Seattle Heart Failure Model (SHFM) prognostic power, a validated risk score for predicting mortality in CHF, is improved by adding B-type natriuretic peptide (BNP). We evaluated in a prospective study the incremental value of several biomarkers, linked to different biological domains, on death risk prediction of BNP-added SHFM.

View Article and Find Full Text PDF